TrialINTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
Trial details
- Registry ID
- NCT03037164
- Phase
- Phase 3
CERS
Cerus Corporation
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
5Trials in this database
15Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceStudy to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients
Trial details
- Registry ID
- NCT03459287
- Phase
- Phase 3
A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.
Trial details
- Registry ID
- NCT06697223
- Phase
- Phase 2
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
Trial details
- Registry ID
- NCT07015437
- Phase
- Phase 2
Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs
Trial details
- Registry ID
- NCT07152379
- Phase
- Phase 2
Latest recorded trial changes
Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs
NCT07152379 · Cerus Corporation
Planned enrollment increased by 15 participants
− Before
10 participants (planned)
+ After
25 participants (planned)
Primary completion date changed
− Before
1 Oct 2027
+ After
30 Sep 2030
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
NCT07015437 · Cerus Corporation
Planned enrollment increased by 50 participants
− Before
70 participants (planned)
+ After
120 participants (planned)
Primary completion date changed
− Before
30 Jul 2026
+ After
15 Dec 2026
A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.
NCT06697223 · Cerus Corporation
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Post infusion recovery of Test platelets at end of 5 day storage
Measure: Post infusion survival of Test platelets at end of 5 Day storage
+ After
Measure: Post Infusion Recovery of Test Platelets at End of 5 Day Storage Measure: Post Infusion Survival of Test Platelets at End of 5 Day Storage
A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.
NCT06697223 · Cerus Corporation
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
60 participants (planned)
+ After
40 participants (actual)
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
Oct 2025
+ After
2 Jun 2025
Recruitment status changed
− Before
Not yet recruiting
+ After
Completed
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
NCT03037164 · Cerus Corporation
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
800 participants (planned)
+ After
692 participants (actual)
Primary completion date changed
− Before
31 Oct 2025
+ After
31 Jul 2026
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1
NCT07015437 · Cerus Corporation
Recruitment status changed
− Before
Not yet recruiting
+ After
Recruiting